| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_304e626dfd0c16bedb8cc39559ca7f76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f33356c524eb32d8bb20d669e34a3241
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_190f636d9246d6a34752e66784a4328f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e92150dd166185ed747e47d84c519915 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-90209
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2007-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12561c434c7e0dfd45eb1bd97a451b43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36197409a983b346c9991af97992926b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a66d05d677fdd838e1567d600da76b3 |
| publicationDate |
2008-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2008062105-A1 |
| titleOfInvention |
Method for predicting the response to a therapy |
| abstract |
The present invention relates to cancer treatment and particularly to a method for predicting the response of a cancer subject to a given therapy. The invention provides a gene or gene product useful as a predictive marker for classifying the subjects. Also disclosed are diagnostic tools, test kits and compositions and their use in the method. The invention is based on the use of NAD(P)H :Quinone oxidoreductase 1, NQOl, which enables the identification and classification of subjects who would benefit from being excluded from a treatment, particularly from anthracycline-based adjuvant chemotherapy with epirubicin. |
| priorityDate |
2006-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |